Press Release

Data showed single subcutaneous doses of D-4517.2 were safe and well tolerated in healthy subjects D-4517.2 exposure in healthy subjects translates to efficacious doses in choroidal neovascularization (CNV) in mouse model Initiation of Phase 2 study evaluating D-4517.2 in patients with neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME) expected in mid-2022 … Read more

Ashvattha Therapeutics (“Ashvattha”), a clinical stage company developing novel hydroxyl dendrimer therapeutics, today announced it has secured $69 million in a Series B financing and in a separate agreement entered an exclusive licensing deal with Huadong Medicine.

Ashvattha will present two oral presentations at the virtual World Molecular Imaging Congress (WMIC), on October 5-8, 2021.

Ashvattha Chairman, CEO and President Jeffrey Cleland, Ph.D., will be presenting at various virtual and in-person investor conferences in September and October.

Ashvattha announced positive interim results from its ongoing multicenter Phase 2 PRANA clinical study of the HDT, OP-101, to treat hyperinflammation in hospitalized adults with severe COVID-19.

Ashvattha will present at the Sachs 7th Annual Immuno-Oncology Innovation Forum, held virtually on May 18-20

Ashvattha announced the presentation of a virtual poster supporting the development of its proprietary HDT, D-4517, for treatment of AMD at the 2021 ARVO Annual Meeting.

Ashvattha initiates a preclinical proof of concept study for OP-801 imaging of neuroinflammation. This Investigational New Drug (IND)-enabling research will be conducted in collaboration with a team of researchers at the Stanford University School of Medicine led by Michelle James, Ph.D., Assistant Professor of Radiology and Neurology.

Ashvattha Therapeutics announced data from a late-breaking presentation at The Liver Meeting Digital Experience 2020 of the American Association for the Study of Liver Diseases (AASLD), held virtually November 13-16, 2020.

Ashvattha announced the formation of a Scientific Advisory Board. The SAB will work closely with Ashvattha’s management team to select and develop highly differentiated HDTs to treat diseases with significant unmet medical need.